Commentary|Podcasts|March 4, 2026

Pharma Pulse: FDA Expands Pediatric Juxtapid Approval and Novo Nordisk Invests €432M in Oral GLP-1 Scaling

In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in its Irish facility to scale global oral GLP-1 production.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I'm your host, and let's get into today's headlines.

  • The FDA has expanded the indication for lomitapide, marketed as Juxtapid, to include pediatric patients aged 2 and older with homozygous familial hypercholesterolemia, or HoFH. This landmark decision addresses an ultra-rare genetic disorder that causes dangerously high LDL levels starting at birth. Clinical data demonstrated a 53.5% mean reduction in bad cholesterol when added to existing therapies. Due to risks of hepatotoxicity, the drug remains available only through a restricted REMS program.
  • Meanwhile, Novo Nordisk is scaling its global manufacturing capacity with a €432 million ($502.6 million) investment to retrofit its facility in Athlone, Ireland. Designated as a primary international manufacturing hub, the site will boost oral GLP-1 production by 2028 to strengthen supply-chain resilience. This investment coincides with a strategic partnership with Vivtex, utilizing AI-enabled modeling and robotics to identify oral biologic formulations with improved intestinal absorption.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.
CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.